[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527637":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":34,"responsibleParty":49,"collaborators":10,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjective or mild cognitive impairment patients",null,"Subjective or mild cognitive impairment patients with or without CPAP treatment",[13],"Device: Continuous Positive Airway Pressure or other management for OSA per clinical indications.",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Continuous Positive Airway Pressure or other management for OSA per clinical indications.","PAP therapy or other management will be advised for subjects with OSA per usual clinical criteria",[9],[21],{"name":22,"affiliation":23,"role":24},"Mary SM Ip, MD","School of Clinical Medicine, The University of Hong Kong","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Sau Man Mary Ip, MD","CONTACT","2255 5885","msmip@hku.hk",{"name":32,"role":28,"phone":10,"phoneExt":10,"email":33},"Yuen Kwan Agnes Lai, PhD","ayklai@hkmu.edu.hk",[35],{"facility":36,"status":37,"city":38,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Queen Mary Hospital","RECRUITING","Hong Kong","HK",{"type":41,"coordinates":42},"Point",[43,44],114.17469,22.27832,{"lat":44,"lon":43},[47,48],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},{"name":32,"role":28,"phone":10,"phoneExt":10,"email":33},{"type":24,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor Mary Ip Sau-man","Emeritus Professor","100527637","sleep-apnea-neurocognitive-decline-and-brain-imaging-in-patients-with-subjective-or-mild-cognitive-impairment-100527637",false,"NCT06150352","Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment","Exploring the Association Between Cognitive Function, Obstructive Sleep Apnea and Brain Imaging, and the Determinants of Neurocognitive Decline in Subjects With Subjective or Mild Cognitive Impairment","Inclusion Criteria:\n\n* Aged 50 - 80 years\n* Diagnosis of mild cognitive impairment based on Peterson's criteria.\n* Diagnosis of subjective cognitive impairment, based on the subjective complaint of cognitive impairment, but with an unremarkable assessment of the Hong Kong version of Montreal cognitive Assessment scores\n* Able to speak and read Chinese\n* Adequate visual and auditory to perform a cognitive test\n* Subjects with moderate-severe OSA or No OSA (diagnosis based on sleep study) would be invited for baseline PET-MRI brain scan\n\nExclusion Criteria:\n\n* Diagnosed psychiatric illness with or without medication, e.g. major depressive disorder.\n* Other clear organic causes of cognitive impairment, e.g. vascular cognitive impairment, brain tumour, dementia with Lewy body, mild cognitive impairment with Lewy body, Parkinson's disease, normal pressure hydrocephalus, neurosyphilis, autoimmune encephalitis, substance abuse, history of alcohol abuse.\n* Diagnosis of cancer on active treatment\n* Contraindications to PET-CT or MRI brain scan (excluded for neuroimaging studies)","ALL","50 Years","80 Years",{"count":63,"type":64},180,"ESTIMATED","OBSERVATIONAL","Obstructive sleep apnea (OSA) is recurrent episodes of partial or complete obstruction of the upper airway during sleep that causes intermittent hypoxia and sleep fragmentation and potentially lead to cardiometabolic and neurocognitive sequelae. Chronic intermittent hypoxia, sleep fragmentation of OSA, and insufficient sleep have been significantly associated with higher risks of neurocognitive impairment, including mild cognitive impairment (MCI) and Alzheimer's disease. Thus, sleep and sleep apnea might be modifiable factors to neurocognitive impairment.\n\nPositive airway pressure (PAP) is the first line of treatment to maintain open airways for patients with OSA. Improving sleep, sleep apnea and circadian function could be a high-value intervention target to alleviate cognitive impairment and decline in subjects with mild neurocognitive impairment.\n\nAmyloid accumulation in brain tissue is a distinct feature of Alzheimers' disease, which is associated with potential impairment of neurocognition clinically. It predicts memory decline in initially cognitively unimpaired individuals.\n\nThe study explores the associations between sleep apnea, cognitive function and cerebral imaging and the role of PAP therapy on neurocognitive trajectory in these patients with subjective cognitive impairment \u002Fmild cognitive impairment (SCI\u002FMCI).",[68,69,70],"Obstructive Sleep Apnea","Mild Cognitive Impairment","Subjective Cognitive Impairment",[72,73,74],"Obstructive sleep apnea","Neurocognitive function","CPAP","2025-03-27",{"date":77,"type":78},"2025-04-02","ACTUAL",{"date":80,"type":78},"2023-09-26",{"date":82,"type":64},"2027-03-31",{"name":5,"class":6},1]